Browse News
Filter News
Found 644,541 articles
-
Nanoform's Clinical Study Indicates Positive Interim Results - Jan 22, 2021
1/22/2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, announced positive interim results from its clinical study.
-
Senseonics Holdings Increases Previously Announced Bought Deal Offering of Common Stock to $100.0 Million
1/22/2021
Senseonics Holdings, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 51,948,052 shares of common stock of the Company at a public offering price of $1.925 per share, less underwriting discounts and commissions.
-
DWHP Announces Extension of The Expiration Time of Its Tender Offer
1/22/2021
DW Healthcare Partners V, L.P., announced that it is extending the expiration time of its previously announced cash tender offer in the Offer to Purchase dated December 21, 2020 for all of the outstanding ordinary shares of Parnell Pharmaceuticals Holdings Ltd at a price of U.S.$0.40 per share, net to the seller in cash without interest and less applicable withholding taxes to 11:59 p.m., New York City time, on January 28, 2021.
-
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19
1/22/2021
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response therapeutics for the treatment of cancer, announced that the first patient has enrolled into an investigator-initiated trial of its investigational drug, Silmitasertib, as a treatment for hospitalized COVID-19 patients at Banner Health-University Medical Center in Phoenix, Arizona.
-
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
1/22/2021
CABENUVA offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression
-
Invitae Announces Pricing of Public Offering of Common Stock - Jan 22, 2021
1/22/2021
Invitae Corporation announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share.
-
Conference call Report on Operations 2020: Vitrolife
1/22/2021
Invitation to attend Vitrolife's conference call regarding presentation of the Report on Operations 2020.
-
Elekta divests its stake in ViewRay
1/22/2021
Elekta AB announced that it has sold its 7.3 percent of the outstanding common stock in ViewRay, Inc. Elekta has no remaining shares in ViewRay after the transaction..
-
Servier and MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs.
-
Less than a year after taking over the reins, Biotechnology Innovation Organization Chief Executive Officer Michelle McMurry-Heath is reorganizing the organization's leadership structure.
-
Hours after being sworn in as the 46th President of the United States, Joe Biden signed 10 executive orders that are aimed at combating the ongoing COVID-19 crisis.
-
Northway Biotech, which was previously Northway Biotechpharma, has opened a new $40 million 30,000-square-foot process development and Current Good Manufacturing Practice (cGMP) manufacturing site in Waltham, Mass.
-
The jury is still out on whether Roche’s arthritis drug, Actemra/RoActemra (tocilizumab), is helpful for the most severe cases of COVID-19.
-
Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
The U.S. FDA has accepted Genentech’s supplemental New Drug Application and has granted Priority Review for the company’s unclassifiable interstitial lung disease (UILD) treatment Esbriet® (pirfenidone).
-
California-based Avidity Biosciences has a goal of disrupting the way RNA-based therapies are delivered to patients through its Antibody-Oligonucleotide Conjugates (AOCs) platform.
-
Money on the Move: January 15-20
1/21/2021
A brief rundown of the biopharmas that brought in the cash the past week. -
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
-
Biotech In-Demand Jobs: Project Managers
1/21/2021
Project managers in the biotech industry play an especially important role on a daily basis.